AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20581337 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced feedback in a virtual environment (RFVE)
Number of subjects: 47
Study 20581337 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 47
Study 17909323 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-learning modules
Number of subjects: 0
Study 17909323 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture/discussion
Number of subjects: 0
Study 15867241 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (200 mg/m2 oral administration)
Number of subjects: 12
Study 12115158 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily plus nimesulide
Number of subjects: 36
Study 12115158 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nimesulide
Number of subjects: 36
Study 11110328 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine sponge bath on Day 1, followed by no bathing for 4 days
Number of subjects: 45
Study 8638531 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (5 micrograms/kg s.c. days 4‐17, 24‐37) during MMM treatment
Number of subjects: 31
Study 8638531 — intervention group
Group type: COMPARATOR
Intervention: Control (MMM alone)
Number of subjects: 31
Study 1448662 — intervention group
Group type: EXPERIMENTAL
Intervention: IA BCNU
Number of subjects: 315
Study 1448662 — intervention group
Group type: COMPARATOR
Intervention: IV BCNU
Number of subjects: 315
Study 1448662 — intervention group
Group type: EXPERIMENTAL
Intervention: IA cisplatin
Number of subjects: 315
Study 1448662 — intervention group
Group type: COMPARATOR
Intervention: IV PCNU
Number of subjects: 315
Study 6580926 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsacrine-containing regimen
Number of subjects: 16
Study 6580926 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin-containing regimen
Number of subjects: 16
Study 30777574 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured diabetes education
Number of subjects: 210
Study 30777574 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 210
Study 29178434 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06273340 400 mg
Number of subjects: 20
Study 29178434 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06273340 50 mg
Number of subjects: 20
Study 29178434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 20
Study 29178434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 20
Study 29178434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27495085 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐INF‐α2a plus ADV (started at week 0)
Number of subjects: 120
Study 27495085 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐INF‐α2a plus ADV (started at week 12)
Number of subjects: 120
Study 27495085 — intervention group
Group type: COMPARATOR
Intervention: PEG‐INF‐α2a monotherapy (group A)
Number of subjects: 120
Study 27495085 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐INF‐α2a plus ADV (started at week 24)
Number of subjects: 120
Study 24556343 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g/day purified long chain omega-3 fatty acids (Omacor)
Number of subjects: 103
Study 24556343 — intervention group
Group type: COMPARATOR
Intervention: 4g/day olive oil (placebo)
Number of subjects: 103
Study 23103485 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen dressing (Suprasorb C) covered with foam dressing (Suprasorb P)
Number of subjects: 10
Study 23103485 — intervention group
Group type: COMPARATOR
Intervention: Foam dressing (Suprasorb P) as primary dressing
Number of subjects: 10
Study 20651749 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost/timolol fixed combination (TTFC)
Number of subjects: 40
Study 20651749 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 40
Study 18341655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaherbs formulation (PHF)
Number of subjects: 28
Study 15978303 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (2 sprays per nostril twice daily)
Number of subjects: 307
Study 15978303 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine (10-mg tablets once daily)
Number of subjects: 307
Study 15978303 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 307
Study 15978303 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 307
Study 12707645 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% cocaine
Number of subjects: 15
Study 12707645 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% oxymetazoline
Number of subjects: 15
Study 12707645 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study 10334231 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 0
Study 10334231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.1-50 micromol)
Number of subjects: 0
Study 8945077 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of oral propafenone administered two hours before pacing (group B)
Number of subjects: 12
Study 8945077 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 12
Study 30288682 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil 6 mg
Number of subjects: 31
Study 30288682 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil 20 mg
Number of subjects: 31
Study 30288682 — intervention group
Group type: COMPARATOR
Intervention: Baloxavir marboxil (various doses: 6, 20, 40, 60, 80 mg)
Number of subjects: 31
Study 30288682 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil (various doses)
Number of subjects: 31
Study 30288682 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil
Number of subjects: 31
Study 27495190 — intervention group
Group type: EXPERIMENTAL
Intervention: Baum cuff (BC)
Number of subjects: 102
Study 24854817 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported unhealthy weight loss behaviors (e.g., fasting, purging)
Number of subjects: 404
Study 24854817 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression (measured by the Center for Epidemiologic Studies Depression short form)
Number of subjects: 404
Study 24854817 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions between gender and depression
Number of subjects: 404
Study 21863477 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric nanoparticles containing celecoxib dosed orally in aqueous suspensions
Number of subjects: 0
Study 21863477 — intervention group
Group type: COMPARATOR
Intervention: Commercial capsules of celecoxib
Number of subjects: 0
Study 21863477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticle suspensions
Number of subjects: 0
Study 20587484 — intervention group
Group type: EXPERIMENTAL
Intervention: freeze-dried 5% IVIg (Gammagard S/D)
Number of subjects: 27
Study 20587484 — intervention group
Group type: EXPERIMENTAL
Intervention: liquid 10% IVIg (Kiovig)
Number of subjects: 27
Study 20587484 — intervention group
Group type: COMPARATOR
Intervention: Gammagard S/D
Number of subjects: 27
Study 17980251 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6140 90 mg twice a day
Number of subjects: 0
Study 17980251 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6140 180 mg twice a day
Number of subjects: 0
Study 17980251 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once a day
Number of subjects: 0
Study 17980251 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6140 (both doses) in clopidogrel pretreated patients
Number of subjects: 0
Study 15793737 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing antibiotics
Number of subjects: 85
Study 15793737 — intervention group
Group type: COMPARATOR
Intervention: Discontinuing antibiotics
Number of subjects: 85
Study 12377396 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (2 g/d)
Number of subjects: 24
Study 12377396 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d)
Number of subjects: 24
Study 12377396 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate and Naltrexone (combined)
Number of subjects: 24
Study 9811045 — intervention group
Group type: EXPERIMENTAL
Intervention: IR501 90 microg
Number of subjects: 99
Study 9811045 — intervention group
Group type: EXPERIMENTAL
Intervention: IR501 300 microg
Number of subjects: 99
Study 9811045 — intervention group
Group type: COMPARATOR
Intervention: Control (IFA alone)
Number of subjects: 99
Study 8580920 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal eating in binge eating disorder patients
Number of subjects: 79
Study 8580920 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal eating in matched-weight controls
Number of subjects: 79
Study 2502013 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 64
Study 2502013 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 64
Study 2502013 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline and Amoxicillin
Number of subjects: 64
Study 899774 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam rectally as a solution (0.7 mg/kg)
Number of subjects: 20
Study 899774 — intervention group
Group type: COMPARATOR
Intervention: Diazepam rectally by suppository (5 mg)
Number of subjects: 20
Study 31283865 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine extended-release (QUEXR300), 300 mg/d
Number of subjects: 0
Study 31283865 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (OLA), 5-20 mg/d
Number of subjects: 0
Study 28801393 — intervention group
Group type: EXPERIMENTAL
Intervention: mWellcare system (mHealth intervention)
Number of subjects: 3702
Study 28801393 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 3702
Study 25444953 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down approach using (99m)technetium dimercaptosuccinic acid renal scintigraphy
Number of subjects: 120
Study 25444953 — intervention group
Group type: COMPARATOR
Intervention: Bottom-up approach using voiding cystourethrography
Number of subjects: 120
Study 25444953 — intervention group
Group type: COMPARATOR
Intervention: Repeat voiding cystourethrography
Number of subjects: 120
Study 25444953 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down approach
Number of subjects: 120
Study 25444953 — intervention group
Group type: COMPARATOR
Intervention: Bottom-up approach
Number of subjects: 120
Study 23784548 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride 0.06 mg/kg
Number of subjects: 183
Study 23784548 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride 0.125 mg/kg
Number of subjects: 183
Study 23784548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 21700683 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice a week (biw)
Number of subjects: 108
Study 21700683 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg once a week (qw)
Number of subjects: 108
Study 21700683 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg biw and qw
Number of subjects: 108
Study 19935987 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback plus relaxation techniques
Number of subjects: 64
Study 19935987 — intervention group
Group type: COMPARATOR
Intervention: Relaxation techniques alone
Number of subjects: 64
Study 17173662 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 kcal/minute nutrient infusion
Number of subjects: 19
Study 17173662 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 kcal/minute nutrient infusion
Number of subjects: 19
Study 17173662 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting PYY concentration
Number of subjects: 19
Study 17173662 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and nutrient-stimulated plasma CCK concentrations
Number of subjects: 19
Study 12634025 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) - three individual diet counseling sessions by a public health nurse, using the Food for Heart Program, referral to a nutritionist if lipid goals not achieved, reinforcement phone call and newsletters.
Number of subjects: 216
Study 12634025 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 216
Study 12634025 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention (MI)
Number of subjects: 216
Study 11000915 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dependence
Number of subjects: 196
Study 11000915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine dependence
Number of subjects: 196
Study 11000915 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine dependence
Number of subjects: 196
Study 9176746 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin plus imipenem-cilastatin (Net + Imi)
Number of subjects: 66
Study 9176746 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin plus ceftazidime (Net + Cef)
Number of subjects: 66
Study 1584658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking
Number of subjects: 20
Study 1584658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking plus rocking
Number of subjects: 20
Study 1584658 — intervention group
Group type: COMPARATOR
Intervention: Stroking intervention
Number of subjects: 20
Study 1584658 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study 2580383 — intervention group
Group type: EXPERIMENTAL
Intervention: ERU-capsules
Number of subjects: 50
Study 2580383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29871370 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous balloon kyphoplasty (Group A)
Number of subjects: 80
Study 29871370 — intervention group
Group type: COMPARATOR
Intervention: PVP with dilated balloon placement (Group B)
Number of subjects: 80
Study 29871370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Group A and Group B)
Number of subjects: 80
Study 27530663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 500 mg given 2 hours or more prior to antivenom therapy (Group A)
Number of subjects: 236
Study 27530663 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydrocortisone at the time of antivenom therapy (Group B)
Number of subjects: 236
Study 23957945 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel every 3 weeks (D3) with prednisone
Number of subjects: 1006
Study 23957945 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone every 3 weeks (M3) with prednisone
Number of subjects: 1006
Study 22169130 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline heart rate (HR) increment of 10 beats/min
Number of subjects: 15193
Study 22169130 — intervention group
Group type: COMPARATOR
Intervention: Highest HR quintile
Number of subjects: 15193
Study 22169130 — intervention group
Group type: COMPARATOR
Intervention: Top baseline HR quintile
Number of subjects: 15193
Study 22169130 — intervention group
Group type: COMPARATOR
Intervention: Highest in-trial HR quintile
Number of subjects: 15193
Study 22169130 — intervention group
Group type: COMPARATOR
Intervention: Highest in-trial HR group
Number of subjects: 15193
Study 19884643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1 mg/m² x 4) and melphalan (200 mg/m²) as conditioning regimen (Bor‐HDM)
Number of subjects: 54
Study 19884643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (Bor‐HDM)
Number of subjects: 54
Study 19884643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bor‐HDM
Number of subjects: 54
Study 19884643 — intervention group
Group type: COMPARATOR
Intervention: HDM alone (control group)
Number of subjects: 54
Study 18540870 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg
Number of subjects: 3
Study 18540870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 3
Study 18540870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 15677511 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy severity assessment using the ETDRS severity scale
Number of subjects: 285
Study 15677511 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal anatomical endpoints assessment
Number of subjects: 285
Study 15677511 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with AER, blood pressure, serum creatinine, and GFR
Number of subjects: 285
Study 12151873 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (AT1-antagonist)
Number of subjects: 0
Study 12151873 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10214783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP; 500 mg twice daily for 10 days, placebo for 4 days)
Number of subjects: 560
Study 10214783 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (CLARI; 500 mg twice daily for 14 days)
Number of subjects: 560
Study 10214783 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (CLARI)
Number of subjects: 560
Study 10214783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP)
Number of subjects: 560
Study 10214783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) and Clarithromycin (CLARI)
Number of subjects: 560
Study 7878711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapor-heated human factor VII concentrate
Number of subjects: 25
Study 7878711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapor-heated human factor IX complex
Number of subjects: 25
Study 7878711 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vapor-heated factor VII concentrate and factor IX complex
Number of subjects: 25
Study 7878711 — intervention group
Group type: COMPARATOR
Intervention: Vapor-heated factor VII concentrate alone
Number of subjects: 25
Study 2170309 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (arm I)
Number of subjects: 100
Study 2170309 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cDDP given once a week (arm II)
Number of subjects: 100
Study 2170309 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with daily cDDP (arm III)
Number of subjects: 100
Study 6104933 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous application of Diazepam, Flunitrazepam, and Benzoctamin in 500 ml physiological NaCl-Solution
Number of subjects: 0
Study 6104933 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of sedatives (implied control)
Number of subjects: 0
Study 31775854 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile anesthesia (sevoflurane or desflurane) during surgery
Number of subjects: 500
Study 31775854 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based total intravenous anesthesia (TIVA) during surgery
Number of subjects: 500
Study 29925363 — intervention group
Group type: EXPERIMENTAL
Intervention: State-owned media
Number of subjects: 902
Study 29925363 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and academic experts and organizations
Number of subjects: 902
Study 29925363 — intervention group
Group type: EXPERIMENTAL
Intervention: Citizen journalists and unofficial social groups
Number of subjects: 902
Study 29925363 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional media posts
Number of subjects: 902
Study 24476774 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery (experimental PU condition)
Number of subjects: 16
Study 24476774 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory arousal (experimental PU condition)
Number of subjects: 16
Study 24476774 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo (control condition)
Number of subjects: 16
Study 24476774 — intervention group
Group type: COMPARATOR
Intervention: Distraction (control condition)
Number of subjects: 16
Study 26208985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone added to risperidone
Number of subjects: 44
Study 26208985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23757456 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CPP‐AC P + 0.2% NaF
Number of subjects: 45
Study 23757456 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CPP‐AC P
Number of subjects: 45
Study 23757456 — intervention group
Group type: COMPARATOR
Intervention: 0.5% NaF mouthrinse
Number of subjects: 45
Study 21385086 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) - five 50-minute sessions over a 10-week period
Number of subjects: 42
Study 21385086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OMT, sham treatment, or physical therapy)
Number of subjects: 42
Study 19177862 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine plus 1 microg mL(‐1) of sufentanil in continuous infusion at a rate of 7 mL h(‐1)
Number of subjects: 43
Study 19177862 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine plus 1 microg mL(‐1) of sufentanil in continuous infusion at a rate of 7 mL h(‐1)
Number of subjects: 43
Study 19177862 — intervention group
Group type: COMPARATOR
Intervention: Rescue analgesia with intravenous ketoprofen and morphine
Number of subjects: 43
Study 16995546 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 92
Study 16995546 — intervention group
Group type: COMPARATOR
Intervention: Conventional LASIK
Number of subjects: 92
Study 14655325 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside Case Management
Number of subjects: 0
Study 14655325 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside Case Management
Number of subjects: 0
Study 14655325 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecommunications Case Management
Number of subjects: 0
Study 14655325 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional case management)
Number of subjects: 0
Study 10709796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention program
Number of subjects: 1795
Study 9106790 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT emulsion
Number of subjects: 10
Study 9106790 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion
Number of subjects: 10
Study 9106790 — intervention group
Group type: COMPARATOR
Intervention: Fat-free TPN
Number of subjects: 10